pI: 7.4623 |
Length (AA): 717 |
MW (Da): 77752 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 10
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
120 | 437 | 1xme (A) | 190 | 509 | 8.00 | 0.000043 | 0.01 | 0.52 | -0.13 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | ME49 Tachyzoite, ME49 Bradyzoite. | Gregory Sibley/Greg |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | VEG Tachyzoite, ME49 Oocyst. | Gregory Fritz HM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | ME49 merozoite. | Hehl AB |
Gregory | ToxoDB |
Sibley/Greg | ToxoDB |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Ortholog group members (OG5_128742)
Species | Accession | Gene Product |
---|---|---|
Candida albicans | CaO19.11618 | Putative membrane transporter of the AAAP family |
Candida albicans | CaO19.4142 | Putative membrane transporter of the AAAP family |
Candida albicans | CaO19.11617 | similar to transmembrane amino acid transporters that control amino acid flux in vacuolar-like organelles |
Candida albicans | CaO19.4141 | similar to transmembrane amino acid transporters that control amino acid flux in vacuolar-like organelles |
Drosophila melanogaster | Dmel_CG13743 | CG13743 gene product from transcript CG13743-RC |
Giardia lamblia | GL50803_95904 | Amino acid transporter system N2, putative |
Homo sapiens | ENSG00000169507 | solute carrier family 38, member 11 |
Leishmania braziliensis | LbrM.31.0470 | amino acid transporter aATP11, putative |
Leishmania braziliensis | LbrM.31.0440 | amino acid transporter aATP11, putative |
Leishmania braziliensis | LbrM.31.0460 | amino acid transporter aATP11, putative |
Leishmania donovani | LdBPK_310350.1 | amino acid transporter, putative |
Leishmania donovani | LdBPK_310370.1 | amino acid transporter aATP11, putative |
Leishmania infantum | LinJ.31.0350 | amino acid transporter aATP11, putative |
Leishmania infantum | LinJ.27.2680 | amino acid permease, putative |
Leishmania infantum | LinJ.31.0370 | amino acid transporter aATP11, putative |
Leishmania infantum | LinJ.31.0360 | amino acid transporter aATP11, putative |
Leishmania major | LmjF.31.0330 | amino acid transporter aATP11, putative |
Leishmania major | LmjF.31.0350 | amino acid transporter aATP11, putative |
Leishmania major | LmjF.31.0340 | amino acid transporter aATP11, putative |
Leishmania major | LmjF.27.0670 | amino acid permease, putative |
Leishmania mexicana | LmxM.27.0670 | amino acid permease, putative |
Leishmania mexicana | LmxM.30.0350 | amino acid transporter aATP11, putative |
Leishmania mexicana | LmxM.30.0340 | amino acid transporter aATP11, putative |
Leishmania mexicana | LmxM.30.0330 | amino acid transporter aATP11, putative |
Mus musculus | ENSMUSG00000061171 | solute carrier family 38, member 11 |
Saccharomyces cerevisiae | YEL064C | Avt2p |
Trypanosoma cruzi | TcCLB.508923.10 | amino acid permease, putative |
Trypanosoma cruzi | TcCLB.511325.40 | amino acid permease, putative |
Trypanosoma cruzi | TcCLB.511325.50 | amino acid permease, putative |
Trypanosoma cruzi | TcCLB.507101.10 | amino acid permease, putative |
Trypanosoma cruzi | TcCLB.510245.10 | amino acid permease, putative |
Toxoplasma gondii | TGME49_226060 | transmembrane amino acid transporter protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
TGME49_226060 this record | Toxoplasma gondii | Essentiality uncertain | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.4